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Abstract
Background: Bluetongue virus (BTV) is an economically important, arthropod borne, emerging pathogen in Europe, causing
disease mainly in sheep and cattle. Routine vaccination for bluetongue would require the ability to distinguish between
vaccinated and infected individuals (DIVA). Current vaccines are effective but are not DIVA. Virus-like particles (VLPs) are
highly immunogenic structural mimics of virus particles, that only contain a subset of the proteins present in a natural
infection. VLPs therefore offer the potential for the development of DIVA compatible bluetongue vaccines.
Methodology/Principal Findings: Merino sheep were vaccinated with either monovalent BTV-1 VLPs or a bivalent mixture
of BTV-1 VLPs and BTV-4 VLPs, and challenged with virulent BTV-1 or BTV-4. Animals were monitored for clinical signs,
antibody responses, and viral RNA. 19/20 animals vaccinated with BTV-1 VLPs either alone or in combination with BTV-4
VLPs developed neutralizing antibodies to BTV-1, and group specific antibodies to BTV VP7. The one animal that showed no
detectable neutralizing antibodies, or group specific antibodies, had detectable viral RNA following challenge but did not
display any clinical signs on challenge with virulent BTV-1. In contrast, all control animals’ demonstrated classical clinical
signs for bluetongue on challenge with the same virus. Six animals were vaccinated with bivalent vaccine and challenged
with virulent BTV-4, two of these animals had detectable viral levels of viral RNA, and one of these showed clinical signs
consistent with BTV infection and died.
Conclusions: There is good evidence that BTV-1 VLPs delivered as monovalent or bivalent immunogen protect from
bluetongue disease on challenge with virulent BTV-1. However, it is possible that there is some interference in protective
response for BTV-4 in the bivalent BTV-1 and BTV-4 VLP vaccine. This raises the question of whether all combinations of
bivalent BTV vaccines are possible, or if immunodominance of particular serotypes could interfere with vaccine efficacy.
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Introduction
Bluetongue is a vector-borne disease of ruminants caused by a
double-stranded RNA (dsRNA) virus of the genus Orbivirus in the
family Reoviridae. In southern Africa, where bluetongue is endemic,
bluetongue virus (BTV) cycles between midges of the Culicoides
genus and wild and domestic ruminants [1]. In livestock, sheep
and cattle can both be affected but sheep generally show the most
severe clinical signs [2,3,4]. Historically, 24 different serotypes of
BTV have been characterized. In addition, Toggenburg virus was
described in 2008 and is considered as a putative 25th BTV
serotype [5,6], and there has been a recent report of a 26th
serotype in Kuwait [7]. Before 1998, outbreaks of bluetongue in
Europe were sporadic and relatively small scale. However, since
then there have been sustained and repeated incursions into the
continent of different serotypes that have had substantial
economic, political and animal welfare impacts [8,9,10,11,12,
13]. A consequence of these outbreaks has been a renewed interest
in the development of vaccines to BTV.
Vaccination is an effective measure to control bluetongue
disease [10]; immunisation with a number of different vaccines
including attenuated virus, inactivated virus, pox-based vaccines
and recombinant protein immunogens result in the induction of
neutralising antibodies and protection against disease and
viraemia [3,10,11,14]. One of the vaccine approaches is the
production of BTV virus like particles (VLPs). VLPs are non-
infectious mimics of the virus formed from expression of only virus
structural proteins in a heterologous expression system [14,15,16].
As these particles do not contain viral genetic material and their
production does not involved the expression of viral transcription
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complex or non-structural protein they are inherently safe and are
compatible with the need to distinguish between infected and
vaccinated animals (DIVA). This is important because one of the
barriers to routine vaccination for livestock disease is the need to
trade between areas where the virus is endemic and areas where it
is exotic [17]. In the case of BTV, construction of VLP involves
the co-expression of four structural proteins, VP2, VP3, VP5 and
VP7 to form a multi-layered particle. VP3 and VP7 form a core
structure which is relatively invariant between serotypes, VP7 is
used as a group-specific antigen for BTV [18]. VP2 and VP5 form
the virus outer capsid, which is responsible for virus attachment
and penetration of host cells, VP2 is the serotype determinant
[1,18].
BTV protection is serotype specific; immunization with one of
the 26 BTV serotypes does not elicit a high cross-protection
against other serotypes. Successful recombinant or inactivated
bivalent and polyvalent vaccines have been described for BTV
that include serotypes 2 and 4 [19], and serotypes 1, 2, 10, 13 and
17 [20]. The strategy behind such multivalent vaccines is that a
cocktail of immunogens to different serotypes will elicit multiple
serotype-specific responses or cross-protective responses. In this
study we test the protective efficacy of a cocktail of BTV VLPs for
BTV-1 and BTV-4 in challenge experiments in Merino sheep,
with the aim of validating that this combination of VLPs provided
protective responses to both viruses. Although there was complete
protection from clinical disease with challenge for BTV-1, there
was some evidence that there was less complete protection for
BTV-4 with the bivalent vaccine.
Results
Development of group specific antibodies in vaccinated
animals
A total of 26 sheep were divided into 5 groups (A–E) and
immunised with monovalent BTV-1 VLPs (Group A), bivalent
BTV-1 and BTV-4 VLPs (Groups B and C) or saline plus adjuvant
only (Groups D and E). In all cases the sheep were immunised
subcutaneously on day 0 and again on day 20 (as Materials and
Methods). The development of a group specific anti-BTV (anti-
VP7) response was monitored in all animals initially using a
commercial competitive ELISA kit (IDVET; Fig. 1A and 1B). No
animal showed a positive result for VP7 recognition at the start of
the experiment (day 0). The results from the competitive ELISA
test showed that only 7 of the 20 VLP vaccinated animals were
positive on the day of the booster immunisation (day 21). After the
second vaccination, 19 of the 20 sheep vaccinated sero-converted
after 2 weeks of the booster-vaccination (day 35). None of control
animals developed antibodies to BTV VP7 prior to challenge with
virulent virus, remaining above the threshold of 35% VP7
Competition. One VLP vaccinated sheep (sheep A2), did not
develop any positive competitive ELISA result for BTV group
specific antigen until 10 days after challenge (day 58). This timing
is consistent with saline vaccinated control sheep challenged with
the same virus (i.e., BTV-1; Group D), where all 3 sheep first
became positive for BTV group specific antigen using the same
test on day 58 (Fig. 1A). All animals in Group C (BTV-1 and
BTV-4 VLP) raised antibody against the group specific antigen
and sero-converted prior to challenge with virulent BTV-4, while
the Group E (control) were sero-converted only after challenge as
expected (Fig. 1B). The results from competitive ELISA were
validated using an alternate commercially available, a double
recognition ELISA test (Ingenasa). In contrast to the competition
ELISA results, all sera from animals vaccinated with VLPs (groups
A–C), were positive for BTV group specific antigen from 10 days
Figure 1. Group specific immune response of sheep vaccinated
with VLPs. Sero-conversion of vaccinated sheep was monitored using
competitive ELISA (POURQUIERH Bluetongue Competitive ELISA)
specific to VP7, the BTV group specific core antigen. V1 and V2 indicate
the day sheep were vaccinated and boosted with immunogen,
respectively. C indicates the day sheep were challenged with virulent
BTV. The data represented is the average of all animals in each group,
no adjustments or omissions have been made. The threshold for the
sample to be considered as seropositive for VP7 was 35%. A. ELISA
results of groups of animals were immunised with VLPs and challenged
with virulent BTV-1. All vaccinated animals, except A2 had a BTV group
specific antigen response above threshold as determined by the kit
prior to challenge. None of the control animals had a response prior to
challenge. Average results of groups of sheep vaccinated with different
immunogens are shown: Group D (control:m), Group A (BTV-1 VLPs:X)
and Group B (BTV-1 & BTV-4 VLPs:%). B. ELISA results of groups of
animals vaccinated with VLPs and challenged with virulent BTV-4. All
vaccinated animals had a BTV group specific antigen response prior to
challenge. None of the control animals had a response prior to
challenge. Average results of groups of sheep vaccinated with different
immunogens are shown: Group E, (saline+adjuvant: &) and Group C
(BTV-1 VLPs & BTV-4 VLPs: N).
doi:10.1371/journal.pone.0026666.g001
Bivalent BTV Vaccines
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after the first immunisation and remained positive for the rest of
the experiment.
Development of neutralisation antibodies in to BTV-1
and BTV-4 in VLP vaccinated sheep
Although ELISA to detect antibodies to VP7 is indicative of an
immune response to the VLP immunogens, it is not possible to
distinguish between the response to BTV-1 VLPs and BTV-4
VLPs with this test. VP7 is present in both VLPs and antibodies to
this protein would be cross-reactive. To assess serotype specific
immune responses to VLPs, we carried out virus neutralisation
tests to determine if the serotype specific neutralising antibodies
were raised in vaccinated sheep (Fig. 2). With the exception of
sheep A2, all animals vaccinated with monovalent BTV-1 VLPs
(Group A) or bivalent BTV-1 and BTV-4 VLPs (Groups B and C)
had serum neutralising titres of at least 32, with a median titre of
128 (Fig. 2A). Neutralisation of BTV-1 by sheep A2 serum was
indistinguishable from background. Incidentally, sheep A2 also did
not develop an immune response to VP7 until after challenge. The
neutralisation antibody titres to BTV-1 were consistently higher
than those observed to BTV-4. This was highlighted by virus
neutralisation titres of 16 or below for BTV-4 in 7 of the 12 sheep
vaccinated with bivalent immunogens. The remaining 4 of this
group had neutralisation titres ranged from 32 to 64, however, due
to insufficient serum collected from animal C5, it was not possible
to determine whether it had raised neutralisation antibody titre
(Fig. 2B). The median neutralisation titre of BTV-4 for these
animals was 16. Surprisingly, one of the sheep vaccinated with
BTV-1 VLPs (sheep A8) also had neutralisation antibodies against
BTV-4, although at a low titre of 16 (Fig. 2B).
Due to low antibody titres for BTV-4 neutralisation using the 50
TCID50 method, virus neutralisation for groups B and C was
further confirmed by 50% plaque reduction assay which showed
similar level of antibody titres.
Clinical signs in sheep following challenge with virulent
virus
As a majority of the sheep vaccinated with VLPs had
demonstrated a group specific or neutralising antibody response,
sheep in all groups were challenged on day 48 with virulent virus.
Groups A, B and D were challenged with BTV-1, groups C and E
were challenged with BTV-4. All animals in control groups D and
E (6/6 animals), showed clinical signs that were consistent with
infection with BTV from day 58 (Fig. 3A and 3B), with the most
severe visible clinical signs observed in animals challenged with
virulent BTV-1 (Fig. 3A). In contrast, none of the animals
vaccinated with monovalent or bivalent immunogens containing
BTV-1 VLPs (groups A and B) showed any detectable gross
clinical signs or increased temperature (Fig. 4). Only the control
animals had an increase in rectal temperature after challenge with
virulent BTV-1. The febrile response in the control animals lasted
greater than 8 days, with temperatures failing to return to normal
during the course of the experiment (Fig. 4A). No increase in rectal
temperature was recorded in any of the animals that were
immunised with BTV-1 VLPs or BTV-1 and BTV-4 VLPs after
challenge with BTV-1 (Fig. 4A). Control animals in group D
challenged with BTV-1 showed pyrexia from day 54 to day 61, but
animals in VLP groups A and B, including sheep A2, had no
detectable pyrexia in this period. With the parallel, challenge of
groups C and E with BTV-4, results were quite different. The
control group animals (group E) displayed clinical signs for a short
duration of time and an increase in rectal temperature above
normal between days 55 and 57 (Fig. 4B). For the animals
vaccinated with the bivalent vaccine (group C) 5/6 animals
showed no clinical signs (Fig. 3B) including no increase in body
temperature over the challenge study (Fig. 4B). However, one
animal, C5 had a transient increase in rectal temperature between
days 54 and 56 and on day 65. This animal also showed apathy,
mandibular oedema, hypersalivation and dyspnoea on day 65 and
died on day 66.
Detection of viral RNA of challenge virus in vaccinated
animals
Although only 1/20 VLP vaccinated, challenged animals (sheep
C5) showed any detectable clinical signs we were interested to
determine whether there was any detectable viral RNA in
challenged animals. Whole blood samples from all animals before
and after challenge were taken (as Materials and Methods) and
presence of viral RNA was determined by quantitative RT-PCR.
The background cycle threshold (Ct) with the RT-PCR test for all
samples was 40. Animals vaccinated with saline and adjuvant and
challenged with virulent BTV-1 had individual Ct values ranging
from 34.62 to 26.55 from day 51 to day 68 with peak viraemia on
Figure 2. Neutralisation antibody response of sheep vaccinat-
ed with VLPs. Virus neutralisation antibody titres of individual sheep
vaccinated with BTV-1 VLP (black), BTV-1 & BTV-4 VLP (grey), BTV-1 &
BTV-4 VLP (white) and non-vaccinated sheep (black and white striped or
spotted bars) prior to challenge with virulent virus as determined by the
neutralisation of 50 TCID50. The group of each animal is indicated by an
A, B, C, D or E alongside the animal number. The serum neutralisation
titres against BTV-4 were not determined for animals A6 (Group A) and
C5 (Group C) due to lack of serum collected. A. Neutralisation
antibodies elicited against BTV-1. B. Neutralisation antibodies elicited
against BTV-4. Titres below the threshold of the assay (dashed line)
were considered to be negative.
doi:10.1371/journal.pone.0026666.g002
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day 54, where the average Ct was 27.57 (Fig. 5A). For the animals
vaccinated with monovalent or bivalent BTV-1 VLPs and
challenged with the same virus (Groups A and B) only 1 animal
(sheep A2) had a Ct different to background. This was the same
sheep that had failed to elicit neutralising or group specific
antibodies and it had detectable viral RNA from day 51 to day 61.
Although, viraemia and Ct values recorded for this animal
mirrored the viraemia for the control animals challenged with
same virus BTV-1 (Table S1), it had no clinical signs of bluetongue
disease. All animals in vaccinated with the bivalent VLPs and
challenged with virulent BTV-1 (Group B) had no detectable
viraemia following virulent virus challenge (Fig. 5A).
All animals had a Ct value of 40 prior to challenge with virulent
BTV-4 indicating that there was no detectable BTV dsRNA
(Fig. 5B). In the control animals, detectable viral RNA peaked at
day 54, down at day 57 and increased again at day 61 (Fig. 5B).
The variation observed in control animals was due to the onset of
viraemia occurring on different days for each animal; no omission
or adjustment of the data points were made, to allow a fair
comparison between treatment groups. Circulating BTV RNA
was detected in sheep E3 and E1 on days 51 and 54, respectively.
In sheep E2, detectable RNA was delayed by 10 days in
comparison to the other control animals with viral RNA first
detected on day 61 (Table S1). All control animals had Ct values
below 40 on day 61 and day 68 (Fig. 5B). The range of Ct values
through this viraemic period were from 27.67 (sheep E3, day 57)
to 38.17 (sheep E2, day 68). Two of the six sheep vaccinated with
BTV-1 and BTV-4 VLPs and challenged with virulent BTV-4 had
detectable viral RNA (sheep C5 and C6). Sheep C5 had detectable
RNA from day 51 until its death on day 65 with Ct values in the
range from 29.4 to 33.97 (Table S1). Sheep C6 was positive on a
single day (day 61) with a Ct value of 35.62 but samples before and
after this from the same sheep were negative. All other sheep
vaccinated with the bivalent VLPs did not develop viraemia after
challenge with virulent BTV-4 and had Ct values below the limit
of detection (Fig. 5B).
Discussion
Previous studies have demonstrated the assembly of BTV-1 and
BTV-4 VLPs [21,22]. However, prior to this study there has been
Figure 3. The average clinical score of sheep challenged with
virulent BTV-1 (A) or BTV-4 (B). All sheep vaccinated with BTV-1
VLPs (Group A; black bar), BTV-1 & BTV-4 VLP (Group B; grey bar) and
challenged with virulent BTV-1 were protected from detectable disease.
All control sheep challenged with BTV-1 (Group D; striped bar)
developed clinical signs of bluetongue disease. Sheep vaccinated with
BTV-1 and BTV-4 VLPs (Group C; white bar) and challenged with BTV-4
show some clinical score on this chart because of one animal (C5). No
other animal in the group showed clinical signs of bluetongue. The
control animals challenged with BTV-4 (Group E; spotted bars)
developed mild clinical bluetongue. Individual sheep were scored on
a standard, 8 point clinical reaction scale. Data presented in the chart is
the average score for each group.
doi:10.1371/journal.pone.0026666.g003
Figure 4. Temperature response of sheep challenged with
virulent BTV. The average rectal temperatures (uC) of BTV-1 VLP
(Group A) and BTV-1 & BTV -4 VLP (Group B and C) vaccinated and
saline vaccinated sheep (Group D and E) were monitored after
challenge. The time of challenge is indicated by an arrow. All animals
in each group were included in the analysis. A. Animals challenged with
virulent BTV-1. The different groups are indicated; Group D (m), Group A
(X) and Group B (%). B. Animals challenged with virulent BTV-4. The
different groups are indicated; Group E (&) and Group C (N).
doi:10.1371/journal.pone.0026666.g004
Bivalent BTV Vaccines
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no investigation of the immunogenicity of these VLPs in sheep or
whether VLPs for these two serotypes could be combined to make
a bivalent vaccine. In this study we have addressed these questions.
Initially, antibodies to group specific antigen VP7 were used as
an indication of immune response in vaccinated sheep. Two
commercial ELISA kits were used for this purpose, one double
recognition ELISA kit (Ingenasa) and one competitive ELISA kit
(IDVET). The double recognition ELISA kit gave an earlier
indication of immune response to VLPs, but the competitive
ELISA was more indicative of overall immune response of the
animal to the vaccine. The sensitivity of both of the ELISA kits to
determine sero-conversion of animals to the group specific antigen
(VP7) requires greater comparison due to the different results in
regards to the time of sero-conversion from the same serum
sample. This is most evident for sheep A2, which was positive from
day 10 for the double recognition ELISA, but remained negative
in the competitive ELISA until after challenge. This sheep was also
the only animal vaccinated with BTV-1 VLPs that had detectable
RNA for the challenge virus by RT-PCR, and the only animal
with a background level of serum neutralisation assay to BTV-1 on
day 30. Despite these findings sheep A2 was completely protected
from clinical signs including pyrexia on challenge. This is a
marked contrast to control animals challenged with the same virus
(Group D). The detection of limited virus replication in a small
proportion of vaccinated animals is consistent with current
commercial inactivated vaccines to bluetongue virus serotype 8
[23,24]. Interestingly, in these studies virus replication on
challenge was also correlated with generally poor immune
response to the vaccine [23] or lack of neutralising antibodies [24].
Challenge experiments with sheep vaccinated with bivalent
VLP vaccine and challenged with BTV-4 resulted in one
vaccinated animal (C5) developing prolonged viraemia and
clinical signs consistent with BTV infection prior to death. One
other animal (C6) was positive for BTV by RT-PCR on one day
following challenge (day 61) but developed no clinical signs and no
persistent viraemia. These results were surprising because a
previous study with VLPs of a different European isolate (BTV-
2) with similar amount of antigens in a different breed of sheep and
challenge virus used as a monovalent vaccine had resulted in
complete abrogation of clinical signs and detectable virus
replication in all vaccinated animals following challenge [21].
Quality control by SDS-PAGE and electron microscopy with the
BTV-1 and BTV-4 VLPs had not revealed a difference between
serotypes in the quality of VLPs used for immunisation. With the
sample sizes used in this study it is unclear whether the reason for
the failure of the bivalent vaccine to protect animal C5 was due to
interference in immune response to BTV-4 VLP caused by
immunodominance of BTV-1 VLP, or whether this animal was
just extremely poor at responding to the vaccine, as for sheep A2
and C6, or was particularly susceptible to infection with BTV.
Previous studies have noted a marked difference in susceptibility
between breeds, species and individuals for development of clinical
disease to BTV [4,23,25]. It is interesting to note that none of the
control animals challenged with the same virus died, suggesting
that there was something unusual in the ability of this animal to
respond to BTV infection. It could be that heightened clinical
signs in these two BTV-4 challenged sheep were related to route of
inoculation. There is some evidence that intradermal delivery of
challenge virus results in clearer disease [26]. However, this does
not explain the difference between the sheep that died (C5) and the
controls challenged with the same virus. Other studies with
monovalent BTV VLPs and intradermal challenge indicate that
protection is achieved even with this route for the virulent
challenge virus [27]. One further possibility is that the BTV-4
VLPs were ineffective as an immunogen and the protection from
BTV-4 challenge was due to cross-protection from BTV-1 VLP
immunisation. This is unlikely, as previous studies indicate that
immunological protection from BTV infection with monovalent
vaccines is usually serotype specific [20,28]. There is some limited
evidence of cross protection against phylogenetically related
serotypes [20] but BTV-1 and BTV-4 do not have a close
relationship in this respect. There is also one recent report
Figure 5. Detection of viraemia in vaccinated animals following
challenge with virulent BTV. BTV genomic RNA was detected in
blood samples by quantitative RT-PCR follow throughout the experi-
ment. None of the animals had any detectable viral RNA prior to
challenge. Each Ct values represented is the average of all animals in
each group, no adjustments or omissions have been made. A. Animals
were challenged with virulent BTV-1. Post- challenge, none of the sheep
vaccinated with bivalent BTV-1 & BTV-4 VLPs vaccine (Group B) had
detectable viraemia, one sheep vaccinated with monovalent BTV-1 VLPs
(Group A) had detectable viraemia and all saline vaccinated control
animals (Group D) had detectable viraemia. The different groups are
indicated; Group D (m), Group A (X) and Group B (%). B. Animals were
challenged with virulent BTV-4. All control animals (Group E) developed
viraemia, while 2 of the 6 animals vaccinated with bivalent BTV-1 & BTV-
4 VLPs vaccine (Group C) had detectable viral dsRNA. The different
groups are indicated; Group E (&) and Group C (N).
doi:10.1371/journal.pone.0026666.g005
Bivalent BTV Vaccines
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suggesting cell-mediated protection from severe disease from a
heterologous seroptype following use of an inactivated vaccine
[29]. This is not generally consistent with other observations on
immunity to bluetongue [28]. However, given the unexpected
results in this study, future studies should include a specific control
group for the monovalent BTV-4 VLP immunogen and larger
groups of animals in order to assess the potential for cross-
protection and immunodominance in BTV cocktail vaccines.
Materials and Methods
Viruses and cells
Bluetongue virus neutralisation tests were carried out using BSR
cells (a derivative of baby hamster kidney cells, ATCC) cultured in
Dulbecco’s modified Eagle medium (DMEM) supplemented with
10% fetal calf serum. Cells were incubated in a humidified chamber
at 37oC with 5% CO2. Challenge viruses were a virulent BTV-4
challenge strain, supplied by Merial (virus titre not supplied), and
BTV-1 ALG2006/01 E1/BHK2 (3.8x107 TCID50/ml) supplied by
CISA-INIA. The development of the two different system to
produce recombinant baculoviruses for the production of BTV-1
VLPs and BTV-4 VLPs have been previously described [21,22].
Briefly, all four proteins in the BTV-1 VLP were expressed from 4
different loci throughout the baculovirus genome and were all
derived from BTV-1 RSA. In comparison, the 4 proteins for the
BTV-4 VLP are expressed from 2 different loci (ph and p10), the
outer capsid proteins (VP2 and VP5) are derived from BTV-4
Corsica and the inner capsid proteins are from BTV-10 (VP7) and
BTV-17 (VP3). The recombinant baculoviruses were cultured in Sf9
(Spodoptera frugiperda, ATCC) cells in SF900II serum free medium
(Invitrogen) at 28uC.
Preparation of BTV VLP vaccines
VLPs for immunisation were prepared as described [21,22], with
the exception that 5 mM EGTA was substituted for 10 mM EDTA
in the lysis buffer and samples were not sonicated. The presence of
all four BTV proteins (VP2, VP3, VP5, VP7) in purified VLPs was
validated by SDS-PAGE and western immunoblot using specific
antibodies, and the morphology of the particles was confirmed by
electron microscopy as described previously [21,22,30]. Prior to
immunisation VLP were stored at 4uC.
Vaccination and Challenge experiments in sheep
All the procedures described in this study were carried out
according to Spanish and European regulations on animal welfare
and were approved by the animal experimental committee from the
Complutense University of Madrid (Committee for Animal
Experimentation, UCM, 2003), in line with the National law
(Royal Decree 1201/2005 and Law 32/2007), which are in
accordance with the Directive of the Council of the European
Communities (86/609/EEC). For the vaccination and challenge
study 26, 7–8 month old healthy male Merino sheep were used.
Animals were in-housed in the VISAVET biosafety level 3 facilities
in the Complutense University of Madrid, with ad libitum food and
water. Prior to vaccination challenge study, animals were tested for
BTV and BTV antibodies. Animals were acclimatised to the
experimental facilities 7 days prior the first vaccination and their
health status evaluated to provide a baseline for experiments. Five
groups, of 3–8 animals were segregated randomly. Groups D and E
(3 animals per group) were control animals and were inoculated
with saline plus SEPPIC adjuvant (Montanide ISA 206 VG
consisting of mannide oleate and mineral oil). Group A (8 animals)
was vaccinated with a monovalent BTV-1 VLP vaccine and groups
B and C (each of 6 animals) were vaccinated with the bivalent BTV-
1 and BTV-4 VLP vaccine. The adjuvant was the same for all
vaccines. Animals were vaccinated subcutaneously on day 0 in the
axillary region, and a second booster vaccination was given on day
20 by the subcutaneous route on the back of the neck. On day 48,
groups A, B and D were challenged with 1 ml of BTV1 ALG2006/
01 E1/BHK2 (3.86107 TCID50/ml, provided by CISA-INIA) by
administrated to the jugular vein. Groups C and E were challenged
with 1 ml virulent BTV-4 virus (supplied by Merial) delivered via
intradermal route as described [21]. At the end of the experiment,
days 69 and 75, all animals were euthanased.
Clinical observations and sample collections from
infected sheep
Sheep were observed after challenge with virulent BTV for the
development of classical bluetongue disease symptoms, all
symptoms were recorded. The rectal temperature was measured
(‘‘KrusseH Instant digital thermometer for domestic animals), on
days 47 until day 68 as an indictor of BTV infection. Blood
samples were collected from sheep to monitor antibody response
in plain tubes on days 0, 10, 20, 35, 42, 48, 53, 58, 68 and prior to
euthanasia (day 74 and 75) and heat inactivated for 30 minutes at
56uC. Whole blood samples were also collected into ethylene
diaminetetraacetic acid (EDTA) tubes on days 48, 51, 54, 57, 61,
68, and prior to euthanasia to enable the RT-PCR detection of the
circulating virus.
Group Specific ELISA assays
Antibody responses to BTV group-specific antigen VP7 were
assessed using the ID ScreenH Bluetongue Competition ELISA kit
(ID VET, France) and the BTV DR 12.BTV.K0 double
recognition ELISA (Ingenasa, Ingezim, Spain) according to the
manufacturers protocols.
RNA extraction and RT-PCR
Extraction of viral RNA from blood samples was carried out
using the NucleoSpinH RNA II kit (Macherey-Nagel, Madrid)
according to the manufacturer’s instruction. Quantification of
BTV RNA was carried out using primers specific for BTV
segment 5 on a Mxpro3000H thermocycler (Stratagene) as
described previously [31].
Detection of neutralisation antibody response in the sera
of vaccinated animals
The development of neutralising antibody response to the BTV
VLPs was assessed in BSR cells by plaque reduction and serum
neutralisation with 50 TCID50 as described [21,32,33]. All
dilutions were preformed in triplicate and the assay repeated at
least twice.
Supporting Information
Table S1 The Ct values determined by real time RT-
PCR for animals challenged with either BTV-1 or BTV-4.
Animals with an A, B or C were challenged with virulent BTV-1.
Animals with a D or E were challenged with virulent BTV-4. Day
48 is the day of challenge. A Ct of 40 was considered to be
negative for BTV dsRNA.
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